Ovarian PRP injections to try to improve embryo quality
Ovarian Platelet-Rich Plasma (oPRP) Injections Improvement In IVF Patients Based On Time-Lapse Incubator Culture for Automated Tracking and AI for Embryo Quality Assessment : A Non-Randomized Propsective Self-Controlled Interventional Study
NA · Generation Next Fertility · NCT07020546
This study tries ovarian platelet-rich plasma (PRP) injections to see if they improve embryo development for people doing IVF.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 47 Years |
| Sex | Female |
| Sponsor | Generation Next Fertility (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT07020546 on ClinicalTrials.gov |
What this trial studies
After an initial IVF cycle, participants receive an autologous PRP injection into both ovaries under transvaginal ultrasound guidance and IV sedation roughly 1–2 weeks after the next menstrual cycle begins. A second IVF cycle uses the same stimulation protocol, with a second ovarian PRP injection on stimulation days 2–5, followed by oocyte retrieval and fertilization under the same conditions as the first cycle. Up to 15 embryos per participant are cultured in a time-lapse AI incubator to track morphokinetics, and AI software scores embryo viability and implantation potential. The trial enrolls people without contraindications to IVF or PRP who are willing to undergo two IVF cycles and meet ovarian reserve/AMH requirements.
Who should consider this trial
Good fit: Ideal candidates are people undergoing IVF who have acceptable ovarian reserve and AMH levels, no contraindications to PRP or IVF, and are willing to complete two IVF cycles with the described procedures.
Not a fit: People with anovulation due to menopause or perimenopause or those with medical contraindications to IVF or PRP are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, ovarian PRP injections could improve embryo development and raise the chances of implantation and pregnancy for some people undergoing IVF.
How similar studies have performed: Small uncontrolled series and case reports have suggested possible ovarian function or embryo-quality improvements with ovarian PRP, but randomized, high-quality evidence is limited and results have been inconsistent.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * No none contraindications to IVF or PRP treatment * Adequate ovarian reserves and AMH level * Willingness to undergo two IVF cycles and oPRP treatment Exclusion Criteria: * Anovulation due to menopause or perimenopause * Any health conditions that are contraindicated for IVF or oPRP treatment
Where this trial is running
New York, New York
- Generation Next Fertility — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Jesse Hade, MD — Generation Next Fertility
- Study coordinator: Alicia L Broussard, PhD
- Email: a.broussard@generationnextfertility.com
- Phone: 3174456958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Infertility, Poor Ovarian Reserve, Embryo Growth Disorder, in Vitro Fertilization